CRSwNP

News

Amgen, AZ's Tezspire challenges Dupixent in nasal polyps

Amgen and AstraZeneca's fast-growing asthma drug Tezspire is now poised to take on rival Dupixent in chronic rhinosinusitis with nasal polyps.

News

Stopwatch starts on reviews of GSK's long-acting asthma drug

Regulators have started reviews of GSK's depemokimab, aiming to become the first drug for asthma that can be dosed twice a year.

News

GSK asthma hope depemokimab works in second indication

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Amgen, AZ's Tezspire challenges Dupixent in nasal polyps

Stopwatch starts on reviews of GSK's long-acting asthma drug

GSK asthma hope depemokimab works in second indication

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Editor's Picks